STAT3 mutations in the hyper-IgE syndrome

被引:884
|
作者
Holland, Steven M.
Deleo, Frank R.
Elloumi, Houda Z.
Hsu, Amy P.
Uzel, Gulbu
Brodsky, Nina
Freeman, Alexandra F.
Demidowich, Andrew
Davis, Joie
Turner, Maria L.
Anderson, Victoria L.
Darnell, Dirk N.
Welch, Pamela A.
Kuhns, Douglas B.
Frucht, David M.
Malech, Harry L.
Gallin, John I.
Kobayashi, Scott D.
Whitney, Adeline R.
Voyich, Jovanka M.
Musser, James M.
Woellner, Cristina
Schaeffer, Alejandro A.
Puck, Jennifer M.
Grimbacher, Bodo
机构
[1] NIAID, NIH, Bethesda, MD 20892 USA
[2] NIAID, Hamilton, MT USA
[3] NHGRI, Bethesda, MD 20892 USA
[4] Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA
[5] Sci Applicat Int Corp, NCI, Frederick, MD USA
[6] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
[7] Royal Free Hosp & UCL, London, England
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 357卷 / 16期
关键词
D O I
10.1056/NEJMoa073687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The hyper-IgE syndrome (or Job's syndrome) is a rare disorder of immunity and connective tissue characterized by dermatitis, boils, cyst-forming pneumonias, elevated serum IgE levels, retained primary dentition, and bone abnormalities. Inheritance is autosomal dominant; sporadic cases are also found. Methods We collected longitudinal clinical data on patients with the hyper-IgE syndrome and their families and assayed the levels of cytokines secreted by stimulated leukocytes and the gene expression in resting and stimulated cells. These data implicated the signal transducer and activator of transcription 3 gene (STAT3) as a candidate gene, which we then sequenced. Results We found increased levels of proinflammatory gene transcripts in unstimulated peripheral-blood neutrophils and mononuclear cells from patients with the hyper-IgE syndrome, as compared with levels in control cells. In vitro cultures of mononuclear cells from patients that were stimulated with lipopolysaccharide, with or without interferon-(gamma), had higher tumor necrosis factor (alpha) levels than did identically treated cells from unaffected persons (P=0.003). In contrast, the cells from patients with the hyper-IgE syndrome generated lower levels of monocyte chemoattractant protein 1 in response to the presence of interleukin-6 (P=0.03), suggesting a defect in interleukin-6 signaling through its downstream mediators, one of which is STAT3. We identified missense mutations and single-codon in-frame deletions in STAT3 in 50 familial and sporadic cases of the hyper-IgE syndrome. Eighteen discrete mutations, five of which were hot spots, were predicted to directly affect the DNA-binding and SRC homology 2 (SH2) domains. Conclusions Mutations in STAT3 underlie sporadic and dominant forms of the hyper-IgE syndrome, an immunodeficiency syndrome involving increased innate immune response, recurrent infections, and complex somatic features.
引用
收藏
页码:1608 / 1619
页数:12
相关论文
共 50 条
  • [1] Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome
    Woellner, Cristina
    Gertz, E. Michael
    Schaeffer, Alejandro A.
    Lagos, Macarena
    Perro, Mario
    Glocker, Erik-Oliver
    Pietrogrande, Maria C.
    Cossu, Fausto
    Franco, Josee L.
    Matamoros, Nuria
    Pietrucha, Barbara
    Heropolitanska-Pliszka, Edyta
    Yeganeh, Mehdi
    Moin, Mostafa
    Espanol, Teresa
    Ehl, Stephan
    Gennery, Andrew R.
    Abinun, Mario
    Breborowicz, Anna
    Niehues, Tim
    Kilic, Sara Sebnem
    Junker, Anne
    Turvey, Stuart E.
    Plebani, Alessandro
    Sanchez, Berta
    Garty, Ben-Zion
    Pignata, Claudio
    Cancrini, Caterina
    Litzman, Jiri
    Sanal, Oezden
    Baumann, Ulrich
    Bacchetta, Rosa
    Hsu, Amy P.
    Davis, Joie N.
    Hammarstroem, Lennart
    Davies, E. Graham
    Eren, Efrem
    Arkwright, Peter D.
    Moilanen, Jukka S.
    Viemann, Dorothee
    Khan, Sujoy
    Laszlo Marodi
    Cant, Andrew J.
    Freeman, Alexandra F.
    Puck, Jennifer M.
    Holland, Steven M.
    Grimbacher, Bodo
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : 424 - 432
  • [2] STAT3 signaling and the hyper-IgE syndrome
    Levy, David E.
    Loomis, Cynthia A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (16): : 1655 - 1658
  • [3] AN ATYPICAL PRESENTATION OF STAT3 HYPER-IGE SYNDROME
    Van Mason, J.
    Raje, N.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S121 - S121
  • [4] Association between STAT3 mutations and phenotypic features in Hyper-IgE Syndrome
    Goncalves, Marcos R.
    Junior, Persio R.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB111 - AB111
  • [5] Location of STAT3 hyper-IgE syndrome mutations does not invariably correlate with STAT3 phosphorylation potential
    Chaimowitz, Natalia
    Vargas-Hernandez, Alexander
    Vogel, Tiphanie
    Forbes, Lisa
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (03) : 381 - 381
  • [6] A CASE OF STAT3 HYPER-IGE SYNDROME WITHOUT ECZEMA
    Wong, K.
    Osborn, R.
    Catanzaro, J.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S80 - S80
  • [7] NOVEL STAT3 MUTATION IN A PATIENT WITH HYPER-IGE SYNDROME
    Germinaro, M.
    Reynolds, P. R.
    Hoyte, F. C.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A85 - A85
  • [8] STAT3 Hyper-IgE Syndrome—an Update and Unanswered Questions
    Christo Tsilifis
    Alexandra F. Freeman
    Andrew R. Gennery
    [J]. Journal of Clinical Immunology, 2021, 41 : 864 - 880
  • [9] STAT3 mutation identified in patients with Hyper-IgE syndrome
    Picard, Capucine
    [J]. M S-MEDECINE SCIENCES, 2008, 24 (03): : 242 - 243
  • [10] Hyper-IgE syndrome with a novel mutation of the STAT3 gene
    Minakawa, S.
    Tanaka, H.
    Kaneko, T.
    Matsuzaki, Y.
    Kono, M.
    Akiyama, M.
    Minegishi, Y.
    Sawamura, D.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2016, 41 (06) : 687 - 689